Publicaciones en colaboración con investigadores/as de Universidad Politécnica de Valencia (58)

2024

  1. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

    Cell Communication and Signaling, Vol. 22, Núm. 1

  2. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

  3. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

  3. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  4. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

    Critical Reviews in Oncology/Hematology, Vol. 182

2022

  1. Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 13

2021

  1. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study

    Materials Science and Engineering C, Vol. 122

  2. Analysis of the gut microbiota: An emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 11

  3. Characterization of circulating t cell receptor repertoire provides information about clinical outcome after pd-1 blockade in advanced non-small cell lung cancer patients

    Cancers, Vol. 13, Núm. 12

  4. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

    Frontiers in Oncology, Vol. 11

  5. dPCR application in liquid biopsies: divide and conquer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 1, pp. 3-15

2020

  1. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 20, Núm. 6, pp. 575-582

  2. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

    Translational Lung Cancer Research, Vol. 9, Núm. 4, pp. 1074-1083

2019

  1. Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, pp. ii9

  2. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  4. Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, pp. ii10-ii11

  5. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1

    Scientific Reports, Vol. 9, Núm. 1